Private Equity

Great Estate Blockchain divests its main revenue source after a flawed deal structure implodes, leaving the penny-stock firm seeking a new identity.

Apollo's REIT is liquidating after a strategic review. Is this an isolated move or a bellwether for distress in the commercial real estate finance sector?

The financial giant sets its 2027 Investor Day. Beyond the date, it's a signal of intent for navigating a fractured world with a $4.9T balance sheet.

Adaptive Biotechnologies' new debt offering is more than a financial tune-up; it's a calculated move to sever a costly royalty deal and arm its star MRD division for a separate future.

AIRA ushers in new leadership with Boris Steffen as President, poised to navigate economic turbulence and shape the future of the insolvency profession.

With the hire of 35-year veteran James McNeill, Infinity Aviation signals a bold strategy to scale its operations and challenge giants in the FBO market.

A Texas-based, private equity-backed firm just acquired a beloved local dermatology practice. It’s a story of national expansion, but what does it mean for care?

After 75 years, the Velan family has sold its controlling stake in the iconic valve maker. A deep dive into the C$204M deal and what it means for the future.

A record $10M gift establishes a new research chair, honoring a titan of Canadian finance and positioning Montreal to solve the critical organ shortage.

UWM Holdings publicly blasts the Two Harbors board, alleging bad faith and obstruction while urging shareholders to reject a rival merger in a proxy showdown.

Backed by a $3B milestone, Ascent Developer Solutions is challenging established lenders by opening a Boston hub to tap into New England's real estate market.

This major consolidation creates a logistics giant from the Gulf Coast to Canada, promising enhanced trade resilience but raising questions about competition.

How a bootstrapped apparel brand that hit $150M in revenue chose a new kind of investor: a fund where 250+ elite athletes are partners, not just faces.

A new Bernstein report reveals UHNW families are prioritizing internal resilience and next-gen prep over external market fears, driven by new laws and a deep generational divide.

Dominari Securities' successful $200M fund for the SpaceX IPO isn't just a trade; it's a masterclass in the new mechanics of power and profit on Wall Street.

Lexeo Therapeutics finalizes a pivotal trial for its Friedreich ataxia gene therapy, leveraging a novel trial design and accelerated FDA pathway.

A green finance firm is investing in gas-powered data centers. Stephen Miller analyzes the $15M deal that reveals the pragmatic, and controversial, future of AI.

Aurora Mobile integrates ShengShu's potent Vidu model, a strategic maneuver to challenge giants like OpenAI and Google by offering a unified, production-ready AI video platform.

The deal showcases a masterful exit in a tough market and signals deeper shifts in the pharma R&D landscape, where specialized research partners are king.

While biopharma braces for Medicare price negotiations, Halozyme claims immunity. Is its tech-licensing model the new blueprint for resilience or just a loophole?